Renal improvement in myeloma with bortezomib plus plasma exchange

New England Journal of Medicine

Volumn 364, Issue 24, 2011, Pages 2365-47366

  Burnette, Brian L ^a   Leung, Nelson ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; IMMUNOGLOBULIN LIGHT CHAIN;

CANCER RELAPSE; CAST NEPHROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; HEMODIALYSIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT RESPONSE; URINARY CAST;

EID: 79959304651     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1101834     Document Type: Letter

References (3)

1. Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-8. (Pubitemid 351693147)
2. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143:777-84. [Erratum, Ann Intern Med 2007;146:471.]
3. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9. (Pubitemid 20122064)